Filing includes results of head-to-head Phase 3 clinical trial evaluating Feraheme compared to ferric carboxymaltose injection
Potential approval and launch in the first half of 2018
“Approximately 4.5 million Americans have been diagnosed with IDA and suffer from its debilitating effects.1 This filing brings us closer to the possibility of offering an alternative intravenous treatment option to those patients who have failed or are intolerant to oral iron, including approximately 1.5 million women with IDA who suffer from gynecological issues, including abnormal uterine bleeding," said
The submission is, in part, supported by positive results from a previously announced Phase 3 randomized, double-blind, non-inferiority clinical trial that evaluated Feraheme compared to Injectafer® (ferric carboxymaltose injection) in approximately 2,000 adults with IDA who had failed or could not tolerate oral iron or in whom oral iron was contraindicated. The study met its pre-specified primary endpoint of demonstrating non-inferiority to Injectafer® based on the primary composite endpoint of the incidence of moderate-to-severe hypersensitivity reactions (including anaphylaxis) or moderate-to-severe hypotension. Additionally, the trial met secondary safety and efficacy endpoints, including the demonstration of superiority to Injectafer in efficacy as measured by mean improvement in hemoglobin per gram of iron administered from baseline to week 5. Importantly, there were no meaningful differences in the safety profile between the two agents, with the exception that study results showed a markedly greater incidence of hypophosphatemia (defined by blood phosphorous of <0.6 mmol/L from baseline to week 2) in the patients dosed with Injectafer compared to those in the Feraheme arm of the trial (Feraheme: 0.4% of patients; Injectafer: 38.7% of patients: rate difference: -38.3%; 95% confidence interval: -41.46% to -35.15%).
About Feraheme® (ferumoxytol)
Feraheme received marketing approval from the
Fatal and serious hypersensitivity reactions including anaphylaxis have occurred in patients receiving Feraheme. Initial symptoms may include hypotension, syncope, unresponsiveness, cardiac/cardiorespiratory arrest. Feraheme is contraindicated in patients with a known hypersensitivity to Feraheme or any of its components, or a history of allergic reaction to any intravenous iron product.
For additional product information, please see full Prescribing Information, including Boxed Warning, available at www.feraheme.com.
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
This press release contains forward-looking information about AMAG Pharmaceuticals, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, AMAG’s beliefs regarding the study data, AMAG’s belief that the Feraheme filing brings it closer to the possibility of an alternative intravenous treatment option to these patients who have failed or are intolerant to oral iron; AMAG’s expectations to receive an FDA decision and launch the new indication in the first half of 2018; and beliefs that newborn stem cells have the potential to play a valuable role in the development of regenerative medicine are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
Such risks and uncertainties include, among others, those risks identified in AMAG’s filings with the U.S. Securities and Exchange Commission (
AMAG disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals® and Feraheme® are registered trademarks of
1 Global Intravenous (I.V.) Iron Drugs Market Report: 2015 Edition.
AMAG Pharmaceuticals, Inc.Contacts: Investors: Linda LennoxVice President, Investor Relations 908-627-3424 Media: Katie PayneVice President, External Affairs 202-669-6786